Orthofix International N.V. announced today that the expected launch of Trinity® Evolution™, the next generation adult stem cell-based allograft developed in collaboration with the Musculoskeletal Transplant Foundation (MTF), has been accelerated to May 1st of this year, two months ahead of schedule.
Last December Orthofix and MTF announced the completion of the major development milestone for Trinity Evolution, indicating that the commercialization phase was ahead of schedule and that the novel tissue form was expected to be available by June 2009. Since that time, progress toward commercialization has accelerated, and the two organizations now expect to begin the limited market release of Trinity Evolution by May 1st.
“Our customers are particularly excited about the upcoming launch of Trinity Evolution, which promises to be superior to the current generation of similar tissue forms. Our industry knowledge and dedicated customer base combined with MTF’s logistical and scientific expertise make us uniquely prepared to bring this very novel technology to both the orthopedic and spine markets,” said Alan Milinazzo, President and CEO of Orthofix. “Additionally, the presence of MTF’s allograft consultants in the field, along with our own spine and orthopedic distribution networks, will ensure that the new allograft is widely available to benefit our surgeons and their patients.”
Trinity Evolution is an adult stem cell-based bone growth matrix designed to advance the surgical use of allografts by providing characteristics similar to an autograft used in spinal and orthopedic surgeries.
About Orthofix
Orthofix International, N.V., a global medical device company, offers a broad line of minimally invasive surgical, and non-surgical, products for the spine, orthopedic, and sports medicine market sectors that address the lifelong bone-and-joint health needs of patients of all ages–helping them achieve a more active and mobile lifestyle. Orthofix’s products are widely distributed around the world to orthopedic surgeons and patients via Orthofix’s sales representatives and its subsidiaries, including BREG, Inc. and Blackstone Medical, Inc., and via partnerships with other leading orthopedic product companies. In addition, Orthofix is collaborating in R&D partnerships with leading medical institutions such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, Rutgers University, the Cleveland Clinic Foundation, Texas Scottish Rite Hospital for Children and National Osteoporosis Institute.
Contact:
Orthofix International N.V.
Dan Yarbrough, 617-912-2903
Vice President of Investor Relations
danyarbrough@orthofix.com
Source: Orthofix International N.V.
Last December Orthofix and MTF announced the completion of the major development milestone for Trinity Evolution, indicating that the commercialization phase was ahead of schedule and that the novel tissue form was expected to be available by June 2009. Since that time, progress toward commercialization has accelerated, and the two organizations now expect to begin the limited market release of Trinity Evolution by May 1st.
“Our customers are particularly excited about the upcoming launch of Trinity Evolution, which promises to be superior to the current generation of similar tissue forms. Our industry knowledge and dedicated customer base combined with MTF’s logistical and scientific expertise make us uniquely prepared to bring this very novel technology to both the orthopedic and spine markets,” said Alan Milinazzo, President and CEO of Orthofix. “Additionally, the presence of MTF’s allograft consultants in the field, along with our own spine and orthopedic distribution networks, will ensure that the new allograft is widely available to benefit our surgeons and their patients.”
Trinity Evolution is an adult stem cell-based bone growth matrix designed to advance the surgical use of allografts by providing characteristics similar to an autograft used in spinal and orthopedic surgeries.
About Orthofix
Orthofix International, N.V., a global medical device company, offers a broad line of minimally invasive surgical, and non-surgical, products for the spine, orthopedic, and sports medicine market sectors that address the lifelong bone-and-joint health needs of patients of all ages–helping them achieve a more active and mobile lifestyle. Orthofix’s products are widely distributed around the world to orthopedic surgeons and patients via Orthofix’s sales representatives and its subsidiaries, including BREG, Inc. and Blackstone Medical, Inc., and via partnerships with other leading orthopedic product companies. In addition, Orthofix is collaborating in R&D partnerships with leading medical institutions such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, Rutgers University, the Cleveland Clinic Foundation, Texas Scottish Rite Hospital for Children and National Osteoporosis Institute.
Contact:
Orthofix International N.V.
Dan Yarbrough, 617-912-2903
Vice President of Investor Relations
danyarbrough@orthofix.com
Source: Orthofix International N.V.
0 comments:
Post a Comment